Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer
Sign Up to like & getrecommendations! Published in 2019 at "Gastric Cancer"
DOI: 10.1007/s10120-019-00973-5
Abstract: BackgroundTrastuzumab with cisplatin and fluoropyrimidines improves overall survival (OS) in patients with HER2-positive advanced gastric cancer (AGC). S-1 plus oxaliplatin (SOX) is one of the standard regimens for HER2-negative AGC in Japan. However, few studies… read more here.
Keywords: patients her2; her2 positive; gastric cancer; agc ... See more keywords
Clinical Diagnostic Value of Atypical Glandular Cells in Cervical Cytology: A Single Center Experience From China.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of lower genital tract disease"
DOI: 10.1097/lgt.0000000000000730
Abstract: OBJECTIVE This study aimed to investigate the diagnostic value of atypical glandular cells (AGCs) by analyzing the prevalence and histopathology of AGCs according to cervical cytology. METHODS We retrospectively reviewed and analyzed the demographic characteristics… read more here.
Keywords: agc; agc patients; cervical cytology; cytology ... See more keywords
Tumor mutational burden as a new biomarker for PD-1 antibody treatment in gastric cancer
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Communications"
DOI: 10.1186/s40880-019-0417-1
Abstract: © The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit… read more here.
Keywords: gastric cancer; biomarker; agc; antibody ... See more keywords
Fluoropyrimidine (F) alone versus F plus platinum (P) as first-line chemotherapy in patients (pts) with advanced gastric cancer (AGC) and severe peritoneal metastasis (SPM): A multicenter observational study.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.121
Abstract: 121Background: The standard 1st-line chemotherapy for AGC pts with SPM has not been established. F alone is generally used for their treatment because of difficulty of hydration for dosing of cisplatin (CDDP) in pts with… read more here.
Keywords: line; spm; agc; study ... See more keywords
The association of renal function with safety and efficacy of cisplatin plus S-1 (CS) therapy and docetaxel plus cisplatin plus S-1 (DCS) therapy in patients with advanced gastric cancer (AGC): An exploratory analysis of JCOG1013.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.3_suppl.197
Abstract: 197Background: JCOG1013, a phase III study comparing CS therapy with DCS therapy for AGC, failed to demonstrate the superiority of DCS to CS in overall survival (OS) (Yamada Y, Lancet GH 2019). Bec... read more here.
Keywords: therapy; renal function; cisplatin plus; association renal ... See more keywords